ReviewBiosensors2025
Advances in Research on Isothermal Signal Amplification Mediated MicroRNA Detection of Clinical Samples: Application to Disease Diagnosis.
Review in Biosensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Isothermal nucleic acid amplification techniques: A comprehensive overview on their principle & applications as alternative to PCR.Practical laboratory medicine · 2026Review
- Highly Sensitive Hybridization Chain Reaction-Based miRNA Detection Technology Using Diffusivity Analysis of Fluorescent Probe-Modified miRNA Particles.Sensors (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
With the rapid development of modern molecular biology, microRNA (miRNA) has been demonstrated to be closely associated with the occurrence and development of tumors and holds significant promise as a biomarker for the early detection, diagnosis, and treatment of cancer and other diseases. Therefore, detecting miRNA and analyzing it to determine its biological functions are of great significance for the screening and diagnosis of diseases. However, the intrinsic characteristics of miRNAs, including their low abundance, short sequence lengths, and high family-specific sequence homology, render traditional detection methods such as Northern blot hybridization, microarray use, and reverse transcription quantitative PCR (RT-qPCR) inadequate for meeting the stringent requirements of clinical detection in biological samples, a task requiring accuracy, rapidity, high detection power, specificity, and cost-effectiveness. In recent years, a substantial amount of effort has been put into developing innovative methodologies to address these challenges. In this review, we aim to provide a comprehensive overview of the recent advancements in these methodologies and their applications in clinical biological sample detection for disease diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.